Epidemiological characteristics of myxopapillary ependymoma and factors affecting overall survival: a SEER-based analysis.

IF 1.7 4区医学 Q4 ONCOLOGY Translational cancer research Pub Date : 2024-11-30 Epub Date: 2024-11-18 DOI:10.21037/tcr-24-757

Ge Huang, Zhengyuan Xie, Jinhong Li

{"title":"Epidemiological characteristics of myxopapillary ependymoma and factors affecting overall survival: a SEER-based analysis.","authors":"Ge Huang, Zhengyuan Xie, Jinhong Li","doi":"10.21037/tcr-24-757","DOIUrl":null,"url":null,"abstract":"Background: Myxopapillary ependymoma (MPE) is a rare tumor. Most studies have discussed the clinical symptoms and treatment of individual cases, but limited data are provided on overall survival and its influencing factors. Consequently, we aimed to further explore the epidemiological features of MPE and factors influencing overall survival.Methods: The cohort study extracted information about all patients diagnosed with intracranial MPE from the Surveillance, Epidemiology, and End Results (SEER) 2004-2015. Epidemiological characteristics and prognostic factors after adjustment for different variables were analyzed. Outcomes were 5- and 10-year overall survival. Univariate and multivariate analyses were conducted using the Cox proportional hazards model, with hazard ratios (HRs) and 95% confidence intervals (CIs).Results: A total of 1,026 cases were identified in the SEER database. No significant difference was found between the incidence of total MPE and the incidence of non-malignant MPE from 2004 to 2015, and there was no incidence trend. The incidence of MPE was higher among people aged 30-34 and 45-49 years old. In 2005, 2007 and 2011, the incidence of men was greater than that of women (P<0.001). Blacks had a lower incidence than whites in years other than 2007, 2010, and 2013. The older age (older vs. younger: HR =1.081, 95% CI: 1.055-1.107), widowed status (widowed vs. single/unmarried: HR =3.058, 95% CI: 1.282-7.296), no surgery (surgery vs. no surgery: HR =0.283, 95% CI: 0.126-0.635), and radiotherapy (radiotherapy vs. no radiotherapy: HR =4.355, 95% CI: 2.211-8.578) were significantly adverse prognostic factors.Conclusions: Age, marital status, surgery and radiotherapy are factors influencing the overall survival of MPE patients. Surgery is still the main therapeutic choice, while radiotherapy plays a negative role in the management of MPE. Therefore, prospective research is required to verify and complement our findings for MPE control.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"6154-6164"},"PeriodicalIF":1.7000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Myxopapillary ependymoma (MPE) is a rare tumor. Most studies have discussed the clinical symptoms and treatment of individual cases, but limited data are provided on overall survival and its influencing factors. Consequently, we aimed to further explore the epidemiological features of MPE and factors influencing overall survival.

Methods: The cohort study extracted information about all patients diagnosed with intracranial MPE from the Surveillance, Epidemiology, and End Results (SEER) 2004-2015. Epidemiological characteristics and prognostic factors after adjustment for different variables were analyzed. Outcomes were 5- and 10-year overall survival. Univariate and multivariate analyses were conducted using the Cox proportional hazards model, with hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: A total of 1,026 cases were identified in the SEER database. No significant difference was found between the incidence of total MPE and the incidence of non-malignant MPE from 2004 to 2015, and there was no incidence trend. The incidence of MPE was higher among people aged 30-34 and 45-49 years old. In 2005, 2007 and 2011, the incidence of men was greater than that of women (P<0.001). Blacks had a lower incidence than whites in years other than 2007, 2010, and 2013. The older age (older vs. younger: HR =1.081, 95% CI: 1.055-1.107), widowed status (widowed vs. single/unmarried: HR =3.058, 95% CI: 1.282-7.296), no surgery (surgery vs. no surgery: HR =0.283, 95% CI: 0.126-0.635), and radiotherapy (radiotherapy vs. no radiotherapy: HR =4.355, 95% CI: 2.211-8.578) were significantly adverse prognostic factors.

Conclusions: Age, marital status, surgery and radiotherapy are factors influencing the overall survival of MPE patients. Surgery is still the main therapeutic choice, while radiotherapy plays a negative role in the management of MPE. Therefore, prospective research is required to verify and complement our findings for MPE control.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

黏液乳头状室管膜瘤的流行病学特征和影响总生存的因素：基于seer的分析。

背景：黏液乳头状室管膜瘤是一种罕见的肿瘤。大多数研究讨论的是个体的临床症状和治疗，但关于总生存期及其影响因素的资料有限。因此，我们旨在进一步探讨MPE的流行病学特征和影响总生存的因素。方法：队列研究从2004-2015年监测、流行病学和最终结果（SEER）中提取所有诊断为颅内MPE的患者的信息。分析不同变量校正后的流行病学特征及预后因素。结果是5年和10年的总生存率。采用Cox比例风险模型进行单因素和多因素分析，采用风险比（hr）和95%置信区间（ci）。结果：在SEER数据库中共发现1026例。2004 - 2015年MPE总发生率与非恶性MPE发生率无显著性差异，且无发病趋势。MPE的发病率在30-34岁和45-49岁人群中较高。在2005年、2007年和2011年，男性的发病率高于女性（vs.）。年轻：HR =1.081, 95% CI: 1.055-1.107)、丧偶状态（丧偶vs单身/未婚：HR =3.058, 95% CI: 1.282-7.296）、未手术（手术vs未手术：HR =0.283, 95% CI: 0.126-0.635）和放疗（放疗vs未放疗：HR =4.355, 95% CI: 2.211-8.578）是显著的不良预后因素。结论：年龄、婚姻状况、手术和放疗是影响MPE患者总体生存的因素。手术仍然是主要的治疗选择，而放疗在MPE的治疗中起着消极的作用。因此，需要前瞻性研究来验证和补充我们在MPE控制方面的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.